Kintayl Capital LP Viking Therapeutics, Inc. Transaction History
Kintayl Capital LP
- $141 Billion
- Q1 2025
A detailed history of Kintayl Capital LP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Kintayl Capital LP holds 99,973 shares of VKTX stock, worth $2.86 Million. This represents 1.71% of its overall portfolio holdings.
Number of Shares
99,973
Previous 50,994
96.05%
Holding current value
$2.86 Million
Previous $2.05 Billion
17.66%
% of portfolio
1.71%
Previous 1.89%
Shares
2 transactions
Others Institutions Holding VKTX
# of Institutions
448Shares Held
64.8MCall Options Held
5.8MPut Options Held
3.76M-
Vanguard Group Inc Valley Forge, PA10.2MShares$291 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$172 Million0.01% of portfolio
-
State Street Corp Boston, MA4.93MShares$141 Million0.01% of portfolio
-
Morgan Stanley New York, NY2.59MShares$74.2 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.16MShares$61.7 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.19B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...